Cost effectiveness of long-acting risperidone in Sweden

Applied Health Economics and Health Policy

Volumn 8, Issue 5, 2010, Pages 327-341

  Hensen, Marja ^a   Heeg, Bart ^a   Lthgren, Mickael ^b   Van Hout, Ben ^c  

^a PHARMERIT INTERNATIONAL   (Netherlands)

^b Janssen Cilag   (Sweden)

^c PHARMERIT INTERNATIONAL   (United States)

Author keywords

controlled release drugs; cost utility; haloperidol, therapeutic use; olanzapine, therapeutic use; patient compliance; risperidone, therapeutic use; schizophrenia, treatment

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; PATIENT COMPLIANCE; POPULATION RESEARCH; RISK ASSESSMENT; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; SIMULATION; SWEDEN; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; COST-BENEFIT ANALYSIS; HUMANS; MEDICATION ADHERENCE; MODELS, ECONOMIC; OUTCOME ASSESSMENT (HEALTH CARE); PRESCRIPTION FEES; QUALITY-ADJUSTED LIFE YEARS; RISPERIDONE; SCHIZOPHRENIA; SWEDEN;

EID: 77956284619     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.2165/11536180-000000000-00000     Document Type: Article

References (61)

1. Lichtenstein P, Bjork C, Hultman CM, et al. Recurrence risks for schizophrenia in a Swedish national cohort. Psychol Med 2006 Oct; 36 (10): 1417-1425
2. Freedman R. Schizophrenia. N Engl J Med 2003 Oct 30; 349 (18): 1738-1749
3. Dental and Pharmaceutical Benefits Agency drug database [online]. Available from URL: http://www.tlv.se/beslut/sok/lakemedel/[Accessed 2010 Jun 6]
4. Parellada E. Clinical experience and management considerations with long-acting risperidone. Curr Med Res Opin 2006 Feb; 22 (2): 241-255
5. Keith SJ, Kane JM, Turner M, et al. Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics. J Clin Psychiatry 2004 Jan; 65 (1): 120-131
6. Keith SJ, Pani L, Nick B, et al. Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatr Serv 2004 Sep; 55 (9): 997-1005
7. Heeg B, Buskens E, Knapp M, et al. Modelling the treated course of schizophrenia: development of a discrete event simulation model. Pharmacoeconomics 2005; 23 Suppl. 1: 17-33
8. Laux G, Heeg B, van Hout BA, et al. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. Pharmaco- economics 2005; 23 Suppl. 1: 49-61
9. Chue PS, Heeg B, Buskens E, et al. Modelling the impact of compliance on the costs and effects of long-acting risper- idone in Canada. Pharmacoeconomics 2005; 23 Suppl. 1: 62-74
10. Heeg B, Buskens E, Botteman M, et al. The cost-effectiveness of atypicals in the UK. Value Health 2008 Dec; 11 (7): 1007-1021
11. National Institute for Health and Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care (update). 2009 Mar 25 [online]. Available from URL: http://www.nice.org.uk/CG082 [Accessed 2010 Jun 6]
12. Socialstyrelsen (SoS). Swedish drug market [drug database;online]. Available from URL: http://www.socialstyrelsen. se/statistik/statistikefteramne/ lakemedel [Accessed 2006 Dec 1]
13. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 Sep 22; 353 (12): 1209-1223
14. Schooler N, Rabinowitz J, Davidson M, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005 May; 162 (5): 947-953
15. Csernansky JG, Mahmoud R, Brenner R. A comparison ofrisperidone and haloperidol for the prevention ofrelapse in patients with schizophrenia. N Engl J Med 2002 Jan 3; 346 (1): 16-22
16. Leucht S, Barnes TR, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003 Jul; 160 (7): 1209-1222
17. Tollefson GD, Beasley Jr CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997 Apr; 154(4): 457-465
18. Hunt GE, Bergen J, Bashir M. Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr Res 2002 Apr 1; 54 (3): 253-264
19. Hogarty GE. Depot neuroleptics: the relevance of psychosocial factors. A United States perspective. J Clin Psychiatry 1984 May; 45 (5 Pt 2): 36-42
20. Rubio G, Martinez I, Ponce G, et al. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry 2006 Jul; 51 (8): 531-539
21. Thieda P, Beard S, Richter A, et al. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv 2003 Apr; 54 (4): 508-516
22. Dolder CR, Lacro JP, Dunn LB, et al. Antipsychotic med ication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002 Jan; 159 (1): 103-108
23. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004 Apr; 161 (4): 692-699
24. Fleischhacker WW, Oehl MA, Hummer M. Factors influencing compliance in schizophrenia patients. J Clin Psychiatry 2003; 64 Suppl. 16: 10-13
25. Remington GJ, Adams ME. Depot neuroleptic therapy: clinical considerations. Can J Psychiatry 1995 Apr; 40 (3 Suppl. 1): S5-11
26. Gerlach J. Depot neuroleptics in relapse prevention: advantages and disadvantages. Int Clin Psychopharmacol 1995 Jan; 9 Suppl. 5: 17-20
27. Keks NA, Ingham M, Khan A, et al. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: randomised, controlled, open- label study. Br J Psychiatry 2007 Aug; 191: 131-139
28. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse ofschizophrenia. Int J Neuropsychopharmacol 2003 Dec; 6 (4): 325-337
29. Wirshing DA, Wirshing WC, Kysar L, et al. Novel anti-psychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999 Jun; 60 (6): 358-363
30. Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional anti- psychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003 Aug; 160 (8): 1396-1404
31. Koro CE, Fedder DO, L'italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002 Aug 3; 325 (7358): 243
32. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychot- ics: a systematic review of 1-year studies. Am J Psychiatry 2004 Mar; 161 (3): 414-425
33. Socialstyrelsen Epidemiologiskt Centrum. Statistikdata-baser - diagnoser i slutenvaird 2005 [database; online]. Available from URL: http://www. socialstyrelsen.se [Accessed in 2007 Jan 1]
34. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD index [database; online]. Available from URL: http://www.whocc.no/atc-ddd-index/ [Accessed 2007 Jan 1]
35. Lakemedelsformansnamnden (LFN). Price database. 2007 [online]. Available from URL: http://www.tlv.se/beslut/sok/lakemedel/[Accessed 2010 Jun 6]
36. Landstinget i Ostergotland. Priser och ersattningar for sydostra sjukvardsregionen: Beslut I Regionsjukvardsnamden [online]. Available from URL: http://www.lio.se [Accessed 2010 Jul 5]
37. Socialstyrelsen och Statistiska centralbyran. Jamforelsetal for socialtjansten ar 2005 [online]. Available from URL: http://www.socialstyrelsen. se/statistik/statistikefteramne/Sidor/jamforelsetalforsocialtjansten.aspx [Accessed 2010 Jul 5]
38. x-rates.com [online]. Available from URL: http://www.x-rates.com [Accessed 2007 Aug 7]
39. Statistics Sweden (Statistiska Centralbyran). Inflation in Sweden 1831-2009 [online]. Available from URL: http://www.scb.se/Pages/TableAndChart 33832.aspx [Accessed 2010 Jun 6]
40. Lenert LA, Sturley AP, Rapaport MH, et al. Public pre ferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res 2004 Nov 1; 71 (1): 155-165
41. Zhou H, Isaman DJ, Messinger S, et al. A computer simulation model of diabetes progression, quality of life, and cost. Diabetes Care 2005 Dec; 28 (12): 2856-2863
42. Landy J, Stein J, Brown MM, et al. Patient, community and clinician perceptions of the quality of life associated with diabetes mellitus. Med Sci Monit 2002 Aug; 8 (8): CR543-8
43. Siddique RM, Markowitz J, Engelhart L. Impact of atypical antipsychotic drug sedation on quality of life [abstract no. NR765; plus poster]. American Psychiatric Association 2005 Annual Meeting; 2005 May 21; Atlanta (GA), 283-284
44. Pharmaceutical Benefits Board. General guidelines for economic evaluations from the Pharmaceutical Benefits Board [online]. Available from URL: http://tlv.se/Upload/English/ENG-lfnar-2003-2.pdf [Accessed 2010 Jun 6]
45. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000 May; 17 (5): 479-500
46. National Institute for Clinical Excellence. Guide to the methods of technology appraisal (no.n0515). London: NICE, 2004 Apr [online]. Available from URL: http://www.nice.org.uk/aboutnice/howwework/devnicetech/tech nologyappraisalprocessguides/guide-to-the-methods-of-technology-appraisal- reference-n0515.jsp [Accessed 2010 Jun 6]
47. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003 Jun; 60 (6): 553-564
48. Bagnall AM, Jones L, Ginnelly L, et al. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess 2003; 7 (13): 1-193
49. Geddes J, Freemantle N, Harrison P, et al. Atypical anti-psychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000 Dec 2; 321 (7273): 1371-1376
50. Emsley RA, Raniwalla J, Bailey PJ, et al. A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol 2000 May; 15(3): 121-131
51. Revicki DA, Genduso LA, Hamilton SH, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res 1999 Aug; 8 (5): 417-426
52. Lindenmayer JP, Czobor P, Volavka J, et al. Effects ofatypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. J Clin Psychiatry 2004 Apr; 65 (4): 551-556
53. Turner MS, Stewart DW. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses. J Psychopharmacol 2006 Nov; 20 (6 Suppl.): 20-37
54. Mahmoud RA, Engelhart LM, Janagap CC, et al. Risper-idone versus conventional antipsychotics for schizophrenia and schizoaffective disorder: symptoms, quality of life and resource use under customary clinical care. Clin Drug In- vestig 2004; 24 (5): 275-286
55. Kane JM, Meltzer HY, Carson Jr WH, et al. Aripiprazole for treatment-resistant schizophrenia: results of a multi- center, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry 2007 Feb; 68 (2): 213-223
56. Rabinowitz J, Lichtenberg P, Kaplan Z, et al. Re-hospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanza- pine, or conventional antipsychotics. Am J Psychiatry 2001 Feb; 158 (2): 266-269
57. Tunis SL, Faries DE, Nyhuis AW, et al. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. Value Health 2006 Mar; 9 (2): 77-89
58. Damen J, Thuresson PO, Heeg B, et al. A pharmaco-economic analysis of compliance gains on antipsychotic medications. Appl Health Econ Health Policy 2008; 6 (4): 189-9759.
59. Niaz OS, Haddad PM. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr Scand 2007 Jul; 116 (1): 36-46
60. Olivares JM, Rodriguez-Martinez A, Buron JA, et al. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy 2008; 6 (1): 41-53
61. Chang HC, Tang CH, Tsai SJ, et al. Long-acting injectable risperidone and hospital readmission: a mirror-image study using a national claim-based database in Taiwan. J Clin Psychiatry 2009 Jan; 70 (1): 141